论文部分内容阅读
目的探索利培酮对精神分裂症患者体重与糖代谢的影响.方法收集36例精神分裂症患者使用利培酮治疗,疗程为12周,分别在未用药前和用药12周后测量体重和检测空腹血糖水平进行同体比较.结果本文结果显示,治疗12周后患者平均体重增加1.36 kg,P<0.05,有显著统计学意义；同时在治疗12周后检测空糖血糖与未治疗前空腹血糖比较,平均升高0.13mmol/L,P<0.05,有显著统计学意义.结论利培酮治疗精神分裂症,对患者的体重和空腹血糖有一定程度的影响.“,”Objective: To study the effect of risperidone for schizophrenia patients on the weight and glycometabolism. Method: we compared the weight and the fasting blood glucose respectively,36 cases of schizophrenic patients treated with risperidone before and after 12 weeks . Result: there was significant difference in the mean weight of the patients treated with risperidone for 12 weeks,which increased by 1.36 kilometres (p<0.05). the average fasting blood glucose of the schizophrenics treated for 12 weeks significant increased by 0.13mmol/L (p<0.05). Result: There are some extent effect on the weight and the fasting blood glucose of the patients who were treated with risperidone.